Ph1 Lobeline Interaction Study - 1

• Sponsor: National Institute on Drug Abuse (NIDA) (NIH)
• Overall Status: Unknown status
• CT.gov ID: NCT00439504
• Collaborator: (none)
• Enrollment: 10
• Location: 1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.

Condition or Disease	Intervention/Treatment	Phase
Methamphetamine Dependence	Drug: Lobeline	Phase 1

Study Design

• Study Type: Interventional
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: Double-Blind, Placebo-Controlled, Cross-Over Assessment of Intravenous Methamphetamine and Sublingual Lobeline Interactions

Outcome Measures

Primary Outcome Measures

1. Cardiovascular responses []

Secondary Outcome Measures

1. Subjective effects []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Be between the ages of 18 and 45 years of age

• Be in general good health with a history of methamphetamine (MA) abuse (but not dependence)

• If female and of child bearing potential, agrees to use birth control

• Be able to understand and provide written informed consent

• Have a body mass index between 18 and 30

• Have reported use of (MA) during the past three months without experiencing adverse consequence plus a life time MA or amphetamine use history of at least four occasions of use

• Have a negative drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening and at the time of admission

Exclusion Criteria:

• Please contact site for details

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Langley Porter Psychiatric Institute	San Francisco	California	United States	94143

Sponsors and Collaborators

• National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: Reese Jones, M.D., Langley Porter Psychiatric Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00439504
• Other Study ID Numbers: NIDA-CPU-0012-1
• First Posted: Feb 23, 2007
• Last Update Posted: Jan 11, 2017
• Last Verified: Feb 1, 2007

• Additional relevant MeSH terms: Lobeline

Study Results

No Results Posted as of Jan 11, 2017